For the quarter ending 2025-10-31, PURE had $100K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Net loss | -464 | -2,399 |
| Share-based compensation | 34 | 147 |
| Depreciation and amortization | - | 2 |
| Depreciation | 1 | - |
| Accounts receivable | -85 | 176 |
| Inventories | 96 | 85 |
| Prepaid expenses | 18 | -4 |
| Accounts payable and accrued liabilities | 117 | 205 |
| Interest on note payable | 91 | 287 |
| Net cash used in operating activities | -250 | -2,015 |
| Net proceeds from note payable to related parties | 350 | 2,000 |
| Net cash provided by financing activities | 350 | 2,000 |
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 100 | -15 |
| Cash and cash equivalents at beginning of period | 409 | 424 |
| Cash and cash equivalents at end of period | 509 | 409 |
PURE BIOSCIENCE, INC. (PURE)
PURE BIOSCIENCE, INC. (PURE)